For 40 years, we’ve helped scientists harness the full potential of biology with next-generation technology. Here we share the latest in automated, end-to-end solutions that span research disciplines to advance scientific discovery and improve the quality of human life worldwide.
Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce
Recently, we acquired Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening.
Following our acquisition of Cellesce Ltd, Tanya Samazan from Instrument Business Outlook dove deep into conversation with our President Susan Murphy and Cellesce CEO Vicky Marsh-Durban about how their complementary expertise and technologies will accelerate organoid research.
Molecular Devices and Advanced Solutions Life Sciences collaborate to develop 3D Biology Automation Technologies for Drug Discovery
We are pleased to announce our collaboration with Advanced Solutions Life Sciences to develop 3D biology automation technologies for drug discovery.
Under this partnership, we will commercialize the BioAssemblyBot® 400 (BAB400) for Drug Discovery. Jointly developed by experts from both companies, the BAB400 for Drug Discovery includes specific enhancements to Advanced Solutions’ existing bioprinting platform that helps life scientists overcome the challenges of reproducing consistent, complex organoid models at scale for drug development.
Available for sale across North America and Europe, this out-of-the-box offering of the BAB400 with our ImageXpress® Cellular Imaging Systems enables turnkey automation of cell health monitoring and end-point assays.
Rapidly assess drug response in 2D and 3D breast cancer model systems with a luminescent viability assay
Discover how the SpectraMax® iD5 Multi-Mode Microplate Reader, which has an ultra-cool PMT for low background luminescence and high sensitivity can provide:
Rapid assessment of cell viability in 3D cultures
Highly sensitive luminescent readout
Easy 3D cell culture and assay setup in U-bottom microplates
New Application Spotlight
Automation of the CRISPR-based cell line development workflow
An increase in demand for faster high-throughput cell-line development and better screening in the pharmaceutical space is driving research facilities and companies to automate existing labs. Typical cell-line development requires the screening of tens of thousands of clones to find the best stable cells that yield high amounts of bioproducts.
In this application note, we discuss the automation of a mammalian cell-line development workflow—the automated, integrated screening of transfected cells for edits, monoclonality, and growth assessment.
The growing demand for 3D cell culture and screening models can be limited by technical challenges for the effective handling, processing, and scaling of high-throughput applications. Many researchers have found success in meeting these challenges by implementing automation into their labs.
Whether you are just starting to transition from 2D to 3D biology research, or looking for a fully automated organoid screening solution, we can help you build a personalized, product-agnostic, end-to-end automated workflow to deliver robust, reproducible results—at scale.
Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.